Title | Characterization of the minimal replicator of Kaposi's sarcoma-associated herpesvirus latent origin. |
Publication Type | Journal Article |
Year of Publication | 2005 |
Authors | Hu, J, Renne, R |
Journal | J Virol |
Volume | 79 |
Issue | 4 |
Pagination | 2637-42 |
Date Published | 2005 Feb |
ISSN | 0022-538X |
Keywords | Antigens, Viral, DNA Replication, DNA, Viral, Enhancer Elements, Genetic, Herpesvirus 8, Human, Humans, Nuclear Proteins, Replication Origin, Sarcoma, Kaposi, Terminal Repeat Sequences, Virus Latency |
Abstract | The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV) binds to two sites within the 801-bp-long terminal repeat (TR) and is the only viral protein required for episomal maintenance. While two or more copies of TR are required for long-term maintenance, a single TR confers LANA-dependent origin activity on plasmid DNA. Deletion mapping revealed a 71-bp-long minimal replicator containing two distinctive sequence elements: LANA binding sites (LBS1/2) and an adjacent 29- to 32-bp-long GC-rich sequence which we termed the replication element. Furthermore, the transcription factor Sp1 can bind to TR outside the minimal replicator and contributes to TR's previously reported enhancer activity. |
DOI | 10.1128/JVI.79.4.2637-2642.2005 |
Alternate Journal | J Virol |
PubMed ID | 15681465 |
PubMed Central ID | PMC546548 |
Grant List | R01 CA088763 / CA / NCI NIH HHS / United States R21 CA097939 / CA / NCI NIH HHS / United States R01 CA 88763 / CA / NCI NIH HHS / United States R21 CA97939 / CA / NCI NIH HHS / United States |
Characterization of the minimal replicator of Kaposi's sarcoma-associated herpesvirus latent origin.
Similar Publications
Deep sequencing of candidate genes identified 14 variants associated with smoking abstinence in an ethnically diverse sample. Sci Rep. 2024;14(1):6385. | .
FAIR Header Reference genome: a TRUSTworthy standard. Brief Bioinform. 2024;25(3). | .
Gut Microbiota and Blood Metabolites Related to Fiber Intake and Type 2 Diabetes. Circ Res. 2024;134(7):842-854. | .